Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Forward Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Forward Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Forward Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Forward Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Forward Pharma's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Forward Pharma's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Forward Pharma is high growth as no earnings estimate data is available.
Unable to determine if Forward Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Forward Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Claus Bo Svendsen, MD, PhD has been the Chief Executive Officer and Principal Financial Officer of Forward Pharma A/S since March 1, 2017 and May 2017 respectively. Dr. Svendsen served as Executive Vice President at Forward Pharma A/S from December 2, 2016 to March 1, 2017 and also served as its Vice President of Medical Affairs since June 24, 2016 until December 2, 2016. Dr. Svendsen is responsible for all Medical Affairs activities, including scientific communication strategy and additionally for medical and scientific input into clinical development across all phases of clinical trials. He was a Medical Analyst and Medical Consultant at NB Capital ApS. He joined NB Capital ApS in November 2008. Dr. Svendsen is a Medical Doctor from the University of Copenhagen and has clinical experience from primarily internal medicine and also from surgical departments. Prior to joining Forward Pharma in 2015, he held positions of increasing seniority in the Danish pharmaceutical company Novo Nordisk A/S, including roles of Global Medical Director for Victoza® (liraglutide) late-phase launch in type 2 diabetes and phase III development in type 1 diabetes and for Saxenda® in its regulatory and pre-launch phase for weight management, supporting a successful FDA advisory committee meeting and finally FDA and EMA approval and these roles included management in a matrix organization and global oversight of project-related medical activities. From 2007 to 2009, he worked as a Medical Analyst in Nordic Biotech Advisors ApS, dealing with due diligence of potential investment opportunities. He has research experience from employment at the department of Bacteriology, Mycology and Parasitology at Statens Serum Institut, Copenhagen. Dr. Svendsen’s research has been focusing on sarcoidosis and chronic bacterial infections as well as pulmonary hypertension related to sarcoidosis. He is the author of more than ten papers in international peer-reviewed journals and serves as a Reviewer on the journal of Epidemiology and Infection and World Journal of Pediatrics. He has worked in several countries with a clinical background in internal medicine. He is a recipient of a Young Investigator Award from the Foundation for Sarcoidosis Research in 2009. Dr. Svendsen is an author of 27 publications in international, peer-reviewed journals and >50 abstracts presented at international congresses on pathobiology of sarcoidosis, new molecular biological methods and medical treatment of diabetes and obesity. Dr. Svendsen has held part of his education at a laboratory in Geelong, Victoria, Australia. He graduated as a Medical Doctor from University of Copenhagen in 2003 and completed a PhD in sarcoidosis pathobiology in 2009.
Insufficient data for Claus to compare compensation growth.
Insufficient data for Claus to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Co-Founder & Chairman of the Board
CEO & Principal Financial Officer
Principal Accounting Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Forward Pharma board of directors is about average.
Forward Pharma A/S operates as a biopharmaceutical company. The company focuses on developing FP187, a proprietary formulation of dimethyl fumarate used for the treatment of various inflammatory and neurological indications. Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.